

ASX ANNOUNCEMENT

Results of 2025 Annual General Meeting

26 NOVEMBER 2025

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura** and **Company**) advises that the 2025 Annual General Meeting of shareholders was held as a hybrid meeting at 10.00 am today (Melbourne time) at the offices of K&L Gates, Level 25, South Tower, 525 Collins Street, Melbourne and via Computershare's virtual meeting platform (**Meeting**).

A total of three resolutions were considered by the Company's shareholders at the Meeting. A total of 90 shareholders lodged proxies in respect of the Meeting, representing approximately 2.61% of the total number of shareholders eligible to vote.

Resolutions 1, 2 and 4 were all passed on a poll. Resolution 3, relating to the ratification of shares issued to AFO Investments Pty Ltd, was withdrawn prior to the meeting.

The total number of valid proxies received in respect of each resolution in the Notice of Meeting and votes cast in respect of the three resolutions that were put before the shareholders at the Meeting are included in the table which is attached as Appendix One.

**** ENDS ****

For personal use only

VITURA HEALTH LIMITED

ASX: VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU





About Vitura Health Limited (ASX: VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX: VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy, and supplier online ecosystem, Canview, which sells and distributes 430+ therapeutic product and device SKUs within Australia from roughly 60 international and domestic brands.
- www.canview.com.au
Canview is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists, and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The Canview system is based on a medicines wholesaling platform which seamlessly brings together several disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are several bespoke, internally generated operating procedures and intellectual property assets, supported by the Canview customer support and infield customer engagement teams. Through the integration of the different elements which together make up Canview, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, Canview provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the Canview platform, without the need to input the patient's details. Prescriptions are then sent directly to the Canview patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the nearly 4,500 Australian pharmacies with accounts on Canview for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.
- www.doctorsondemand.com.au
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.
- www.cortexa.com.au
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE: MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- www.cdaclinics.com.au
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- www.cannadoc.com.au
The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

**Authorised by**

Robert Iervasi, Chair and Non-Executive Director

Contact**Vitura Health Limited**

Robert Iervasi
Chair
1300 799 491
info@vitura.com.au

Media enquiries

Dieter Lehmann
Nominis Communications
+61 427 672 995
dieter@nominis.me

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties, and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.

For personal use only

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of the Remuneration Report	Ordinary	233,706,873 99.69%	409,449 0.17%	330,366 0.14%	4,749,905	289,393,164 85.22%	50,199,012 14.78%	4,749,905	Carried
2 Appointment of Robert Iervasi as Director	Ordinary	244,105,520 99.79%	124,084 0.05%	394,967 0.16%	207,122	349,785,484 99.94%	212,575 0.06%	207,122	Carried
3 Ratification of prior Issue of Shares to AFO Investments	Ordinary	Withdrawn							
4 Amendment of Constitution - Electronic Meetings	Special	243,489,181 99.60%	591,035 0.24%	394,968 0.16%	356,509	299,556,513 85.62%	50,292,159 14.38%	356,509	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

For personal use only